Etanercept (Enbrel): Update on therapeutic use

Annals of the Rheumatic Diseases

Volumn 59, Issue SUPPL. 1, 2000, Pages

  Spencer Green, G ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; ETANERCEPT; METHOTREXATE;

ALOPECIA; AREA UNDER THE CURVE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; EPISTAXIS; HUMAN; JOINT DESTRUCTION; JUVENILE RHEUMATOID ARTHRITIS; MOUTH ULCER; NAUSEA; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RASH; RHEUMATOID ARTHRITIS; STEROID THERAPY; VOMITING;

EID: 0033768517     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.59.suppl_1.i46     Document Type: Conference Paper

References (23)

1. Etanercept: Therapeutic use in patients with rheumatoid arthritis
2. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors
3. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts
4. Prostaglandin E2, intedeukin 1α, and tumor necrosis factor-α increase human osteoclast formation and bone resorption in vitro
5. Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1
6. Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist
7. Inhibitory effect of TNFα antibodies on synovial cell interleukin-1 production in rheumatoid arthritis
8. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists
9. Comparative analysis of the ability of etanercept and infliximab to lyse TNF-expressing cells in a complement dependent fashion
10. Influence of a recombinant human soluble tumor necrosis factor receptor Fc fusion protein on type II collagen-induced arthritis in mice
11. Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: Toxicity and dose finding trial in refractory rheumatoid arthritis
12. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein
13. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial
14. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
15. Etanercept in children with polyarticular juvenile rheumatoid arthritis
16. Long-term use of Enbrel in patients with DMARD-refractory rheumatoid arthritis
17. Cancer statistics, 1997
18. A Phase III trial of etanercept vs methotrexate (MTX) in early rheumatoid arthritis (Enbrel ERA trial)
19. Comparison of ACR response, numeric ACR, and ACR AUC as measures of clinical improvement in RA clinical trials
20. Judging disease activity in clinical practice in rheumatoid arthritis: First step in the development of a disease activity score
21. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis
22. Validity of area-under-the-curve analysis to summarize effect in rheumatoid arthritis clinical trials
23. Randomized trial of etanercent (Enbrel) in the treatment of psoriatic arthritis and psoriasis